Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas

NCT00051675 is registered in ClinicalTrials.gov with XOMA (US) LLC as lead sponsor.

NCT NCT00051675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas
Lead sponsor
XOMA (US) LLC
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2002
Completion date
September 30, 2003
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma